Literature DB >> 22543969

Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard.

Bo-Kyeong Kang1, Eun Sil Yu, Seung Soo Lee, Youngjoo Lee, Namkug Kim, Claude B Sirlin, Eun Yoon Cho, Suk Keu Yeom, Jae Ho Byun, Seong Ho Park, Moon-Gyu Lee.   

Abstract

OBJECTIVE: The aims of this study were to assess the confounding effects of hepatic iron deposition, inflammation, and fibrosis on hepatic steatosis (HS) evaluation by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) and to assess the accuracies of MRI and MRS for HS evaluation, using histology as the reference standard.
MATERIALS AND METHODS: In this institutional review board-approved prospective study, 56 patients gave informed consents and underwent chemical-shift MRI and MRS of the liver on a 1.5-T magnetic resonance scanner. To estimate MRI fat fraction (FF), 4 analysis methods were used (dual-echo, triple-echo, multiecho, and multi-interference), and MRS FF was calculated with T2 correction. Degrees of HS, iron deposition, inflammation, and fibrosis were analyzed in liver resection (n = 37) and biopsy (n = 19) specimens. The confounding effects of histology on fat quantification were assessed by multiple linear regression analysis. Using the histologic degree of HS as the reference standard, the accuracies of each method in estimating HS and diagnosing an HS of 5% or greater were determined by linear regression and receiver operating characteristic analyses.
RESULTS: Iron deposition significantly confounded estimations of FF by the dual-echo (P < 0.001) and triple-echo (P = 0.033) methods, whereas no histologic feature confounded the multiecho and multi-interference methods or MRS. The MRS (r = 0.95) showed the strongest correlation with histologic degree of HS, followed by the multiecho (r = 0.92), multi-interference (r = 0.91), triple-echo (r = 0.90), and dual-echo (r = 0.85) methods. For diagnosing HS, the areas under the curve tended to be higher for MRS (0.96) and the multiecho (0.95), multi-interference (0.95), and triple-echo (0.95) methods than for the dual-echo method (0.88) (P ≥ 0.13).
CONCLUSION: The multiecho and multi-interference MRI methods and MRS can accurately quantify hepatic fat, with coexisting histologic abnormalities having no confounding effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543969     DOI: 10.1097/RLI.0b013e31824baff3

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  39 in total

1.  Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease.

Authors:  Susanne Bonekamp; An Tang; Arian Mashhood; Tanya Wolfson; Christopher Changchien; Michael S Middleton; Lisa Clark; Anthony Gamst; Rohit Loomba; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-06       Impact factor: 4.813

2.  Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis.

Authors:  Guido M Kukuk; Kanishka Hittatiya; Alois M Sprinkart; Holger Eggers; Jürgen Gieseke; Wolfgang Block; Philipp Moeller; Winfried A Willinek; Ulrich Spengler; Jonel Trebicka; Hans-Peter Fischer; Hans H Schild; Frank Träber
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

3.  Reproducibility of MR-based liver fat quantification across field strength: Same-day comparison between 1.5T and 3T in obese subjects.

Authors:  Nathan S Artz; William M Haufe; Catherine A Hooker; Gavin Hamilton; Tanya Wolfson; Guilherme M Campos; Anthony C Gamst; Jeffrey B Schwimmer; Claude B Sirlin; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2015-01-23       Impact factor: 4.813

4.  Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.

Authors:  Jennifer C Price; Yifei Ma; Rebecca Scherzer; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  Hepatology       Date:  2017-02-03       Impact factor: 17.425

5.  Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report.

Authors:  Jason Salsamendi; Keith Pereira; Kyungmin Kang; Ji Fan
Journal:  J Radiol Case Rep       Date:  2015-09-30

6.  Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Michael S Middleton; Cynthia Behling; Kimberly P Newton; Hannah I Awai; Melissa N Paiz; Jessica Lam; Jonathan C Hooker; Gavin Hamilton; John Fontanesi; Claude B Sirlin
Journal:  Hepatology       Date:  2015-02-05       Impact factor: 17.425

7.  Quantitative analysis of hepatic fat fraction by single-breath-holding MR spectroscopy with T₂ correction: phantom and clinical study with histologic assessment.

Authors:  Norio Hayashi; Tosiaki Miyati; Takashi Minami; Yumie Takeshita; Yasuji Ryu; Tsuyoshi Matsuda; Naoki Ohno; Takashi Hamaguchi; Kenichiro Kato; Toshinari Takamura; Osamu Matsui
Journal:  Radiol Phys Technol       Date:  2012-12-07

Review 8.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

Review 9.  Radiologic evaluation of nonalcoholic fatty liver disease.

Authors:  Seung Soo Lee; Seong Ho Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Quantification of hepatic steatosis with dual-energy computed tomography: comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse.

Authors:  Nathan S Artz; Catherine D G Hines; Stephen T Brunner; Rashmi M Agni; Jens-Peter Kühn; Alejandro Roldan-Alzate; Guang-Hong Chen; Scott B Reeder
Journal:  Invest Radiol       Date:  2012-10       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.